Does the media favor ALEC or DSGN?

In the previous week, Alector had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Alector and 1 mentions for Design Therapeutics. Alector's average media sentiment score of 0.54 beat Design Therapeutics' score of 0.00 indicating that Alector is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AVTX or ALEC?

In the previous week, Alector had 2 more articles in the media than Avalo Therapeutics. MarketBeat recorded 4 mentions for Alector and 2 mentions for Avalo Therapeutics. Alector's average media sentiment score of 0.54 beat Avalo Therapeutics' score of 0.48 indicating that Alector is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alector 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EVMN or ALEC more profitable?

Evommune has a net margin of 0.00% compared to Alector's net margin of -680.83%. Evommune's return on equity of 0.00% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets Evommune N/A N/A N/A Alector -680.83% -295.17% -40.95%

Does the media prefer EVMN or ALEC?

In the previous week, Alector had 3 more articles in the media than Evommune. MarketBeat recorded 4 mentions for Alector and 1 mentions for Evommune. Alector's average media sentiment score of 0.54 beat Evommune's score of 0.00 indicating that Alector is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evommune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alector 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ALEC or ZVRA more profitable?

Zevra Therapeutics has a net margin of 101.58% compared to Alector's net margin of -680.83%. Zevra Therapeutics' return on equity of 51.49% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets Alector -680.83% -295.17% -40.95% Zevra Therapeutics 101.58% 51.49% 28.86%

Does the media refer more to ALEC or ZVRA?

In the previous week, Alector had 2 more articles in the media than Zevra Therapeutics. MarketBeat recorded 4 mentions for Alector and 2 mentions for Zevra Therapeutics. Alector's average media sentiment score of 0.54 beat Zevra Therapeutics' score of 0.00 indicating that Alector is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alector 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, CYRX or ALEC?

CryoPort has higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CryoPort $176.18M 4.46 $78.30M $1.35 11.54 Alector $21.05M 9.73 -$142.93M -$1.19 N/A

Is CYRX or ALEC more profitable?

CryoPort has a net margin of 41.57% compared to Alector's net margin of -680.83%. CryoPort's return on equity of -7.92% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets CryoPort 41.57% -7.92% -4.79% Alector -680.83% -295.17% -40.95%

Does the media prefer CYRX or ALEC?

In the previous week, Alector had 3 more articles in the media than CryoPort. MarketBeat recorded 4 mentions for Alector and 1 mentions for CryoPort. CryoPort's average media sentiment score of 1.67 beat Alector's score of 0.54 indicating that CryoPort is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Alector 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Alector (ALEC) Competitors

$1.84 +0.02 (+0.82%)

As of 12:31 PM Eastern

Compare

ALEC vs. DSGN, AVTX, EVMN, ZVRA, and CYRX

Should you buy Alector stock or one of its competitors? MarketBeat compares Alector with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alector include Design Therapeutics (DSGN), Avalo Therapeutics (AVTX), Evommune (EVMN), Zevra Therapeutics (ZVRA), and CryoPort (CYRX). These companies are all part of the "pharmaceutical products" industry.

How does Alector compare to Design Therapeutics?

Alector (NASDAQ:ALEC) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.

85.8% of Alector shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Design Therapeutics has a net margin of 0.00% compared to Alector's net margin of -680.83%. Design Therapeutics' return on equity of -33.07% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-680.83%	-295.17%	-40.95%
Design Therapeutics	N/A	-33.07%	-31.29%

In the previous week, Alector had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Alector and 1 mentions for Design Therapeutics. Alector's average media sentiment score of 0.54 beat Design Therapeutics' score of 0.00 indicating that Alector is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Design Therapeutics has lower revenue, but higher earnings than Alector. Design Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	9.73	-$142.93M	-$1.19	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Alector has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

Alector currently has a consensus target price of $3.63, indicating a potential upside of 96.48%. Design Therapeutics has a consensus target price of $16.50, indicating a potential upside of 14.23%. Given Alector's higher possible upside, equities research analysts clearly believe Alector is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Design Therapeutics beats Alector on 9 of the 16 factors compared between the two stocks.

How does Alector compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 8.3% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Avalo Therapeutics has a net margin of 0.00% compared to Alector's net margin of -680.83%. Avalo Therapeutics' return on equity of -97.54% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-97.54%	-72.42%
Alector	-680.83%	-295.17%	-40.95%

Avalo Therapeutics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Alector has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

In the previous week, Alector had 2 more articles in the media than Avalo Therapeutics. MarketBeat recorded 4 mentions for Alector and 2 mentions for Avalo Therapeutics. Alector's average media sentiment score of 0.54 beat Avalo Therapeutics' score of 0.48 indicating that Alector is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alector	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalo Therapeutics presently has a consensus target price of $46.67, indicating a potential upside of 156.41%. Alector has a consensus target price of $3.63, indicating a potential upside of 96.48%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Avalo Therapeutics is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Avalo Therapeutics has higher earnings, but lower revenue than Alector. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$59K	16,215.27	-$78.26M	-$5.46	N/A
Alector	$21.05M	9.73	-$142.93M	-$1.19	N/A

Summary

Avalo Therapeutics beats Alector on 9 of the 16 factors compared between the two stocks.

How does Alector compare to Evommune?

Evommune (NYSE:EVMN) and Alector (NASDAQ:ALEC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

85.8% of Alector shares are held by institutional investors. 8.3% of Alector shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Evommune currently has a consensus price target of $49.25, indicating a potential upside of 97.77%. Alector has a consensus price target of $3.63, indicating a potential upside of 96.48%. Given Evommune's stronger consensus rating and higher possible upside, equities research analysts plainly believe Evommune is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evommune	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Evommune has a net margin of 0.00% compared to Alector's net margin of -680.83%. Evommune's return on equity of 0.00% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evommune	N/A	N/A	N/A
Alector	-680.83%	-295.17%	-40.95%

In the previous week, Alector had 3 more articles in the media than Evommune. MarketBeat recorded 4 mentions for Alector and 1 mentions for Evommune. Alector's average media sentiment score of 0.54 beat Evommune's score of 0.00 indicating that Alector is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evommune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alector	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evommune has higher earnings, but lower revenue than Alector. Evommune is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evommune	$13M	69.00	-$68.87M	-$9.50	N/A
Alector	$21.05M	9.73	-$142.93M	-$1.19	N/A

Summary

Evommune beats Alector on 9 of the 16 factors compared between the two stocks.

How does Alector compare to Zevra Therapeutics?

Alector (NASDAQ:ALEC) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

In the previous week, Alector had 2 more articles in the media than Zevra Therapeutics. MarketBeat recorded 4 mentions for Alector and 2 mentions for Zevra Therapeutics. Alector's average media sentiment score of 0.54 beat Zevra Therapeutics' score of 0.00 indicating that Alector is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zevra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zevra Therapeutics has a net margin of 101.58% compared to Alector's net margin of -680.83%. Zevra Therapeutics' return on equity of 51.49% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-680.83%	-295.17%	-40.95%
Zevra Therapeutics	101.58%	51.49%	28.86%

Alector has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

Alector currently has a consensus price target of $3.63, suggesting a potential upside of 96.48%. Zevra Therapeutics has a consensus price target of $29.29, suggesting a potential upside of 121.71%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Zevra Therapeutics is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82

85.8% of Alector shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Zevra Therapeutics has higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	9.73	-$142.93M	-$1.19	N/A
Zevra Therapeutics	$122.29M	6.39	$83.23M	$1.99	6.64

Summary

Zevra Therapeutics beats Alector on 11 of the 16 factors compared between the two stocks.

How does Alector compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Alector (NASDAQ:ALEC) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

92.9% of CryoPort shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 10.1% of CryoPort shares are held by insiders. Comparatively, 8.3% of Alector shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

CryoPort has higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.46	$78.30M	$1.35	11.54
Alector	$21.05M	9.73	-$142.93M	-$1.19	N/A

CryoPort currently has a consensus price target of $15.11, indicating a potential downside of 3.01%. Alector has a consensus price target of $3.63, indicating a potential upside of 96.48%. Given Alector's higher possible upside, analysts clearly believe Alector is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

In the previous week, Alector had 3 more articles in the media than CryoPort. MarketBeat recorded 4 mentions for Alector and 1 mentions for CryoPort. CryoPort's average media sentiment score of 1.67 beat Alector's score of 0.54 indicating that CryoPort is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Alector	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CryoPort has a net margin of 41.57% compared to Alector's net margin of -680.83%. CryoPort's return on equity of -7.92% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Alector	-680.83%	-295.17%	-40.95%

CryoPort has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market. Comparatively, Alector has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Summary

CryoPort beats Alector on 13 of the 16 factors compared between the two stocks.

Get Alector News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALEC vs. The Competition

Export

Metric	Alector	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$204.85M	$3.51B	$6.55B	$12.20B
Dividend Yield	N/A	2.30%	2.69%	5.82%
P/E Ratio	-1.55	20.74	25.18	24.19
Price / Sales	9.73	331.77	554.67	122.21
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	6.59	8.37	10.82	6.51
Net Income	-$142.93M	$23.85M	$3.56B	$337.14M
7 Day Performance	18.27%	4.15%	1.98%	0.26%
1 Month Performance	-16.52%	3.45%	1.43%	1.22%
1 Year Performance	23.83%	57.37%	31.13%	28.88%

Alector Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALEC Alector	2.8172 of 5 stars	$1.85 +0.8%	$3.63 +96.5%	+33.1%	$204.85M	$21.05M	N/A	270	News Coverage Gap Down
DSGN Design Therapeutics	1.5281 of 5 stars	$12.44 flat	$16.50 +32.6%	+252.3%	$776.97M	N/A	N/A	40
AVTX Avalo Therapeutics	3.1649 of 5 stars	$14.70 flat	$46.67 +217.5%	+272.2%	$772.71M	$60K	N/A	40	News Coverage High Trading Volume
EVMN Evommune	2.1046 of 5 stars	$21.27 -0.4%	$49.25 +131.5%	N/A	$769.35M	$10M	N/A	45
ZVRA Zevra Therapeutics	4.0667 of 5 stars	$12.90 flat	$29.29 +127.0%	+44.4%	$762.59M	$106.47M	6.48	20	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALEC) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alector (ALEC) Competitors

ALEC vs. DSGN, AVTX, EVMN, ZVRA, and CYRX

How does Alector compare to Design Therapeutics?

Summary

How does Alector compare to Avalo Therapeutics?

Summary

How does Alector compare to Evommune?

Summary

How does Alector compare to Zevra Therapeutics?

Summary

How does Alector compare to CryoPort?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC vs. The Competition

Alector Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alector (ALEC) Competitors

ALEC vs. DSGN, AVTX, EVMN, ZVRA, and CYRX

How does Alector compare to Design Therapeutics?

Do institutionals and insiders believe in ALEC or DSGN?

Is ALEC or DSGN more profitable?

Does the media favor ALEC or DSGN?

Which has higher valuation and earnings, ALEC or DSGN?

Which has more risk & volatility, ALEC or DSGN?

Do analysts prefer ALEC or DSGN?

Summary

How does Alector compare to Avalo Therapeutics?

Do institutionals and insiders believe in AVTX or ALEC?

Is AVTX or ALEC more profitable?

Which has more volatility & risk, AVTX or ALEC?

Does the media favor AVTX or ALEC?

Do analysts rate AVTX or ALEC?

Which has preferable valuation and earnings, AVTX or ALEC?

Summary

How does Alector compare to Evommune?

Do insiders and institutionals hold more shares of EVMN or ALEC?

Do analysts prefer EVMN or ALEC?

Is EVMN or ALEC more profitable?

Does the media prefer EVMN or ALEC?

Which has preferable valuation & earnings, EVMN or ALEC?

Summary

How does Alector compare to Zevra Therapeutics?

Does the media refer more to ALEC or ZVRA?

Is ALEC or ZVRA more profitable?

Which has more risk and volatility, ALEC or ZVRA?

Do analysts prefer ALEC or ZVRA?

Do insiders & institutionals hold more shares of ALEC or ZVRA?

Which has preferable earnings and valuation, ALEC or ZVRA?

Summary

How does Alector compare to CryoPort?

Do insiders & institutionals believe in CYRX or ALEC?

Which has better valuation and earnings, CYRX or ALEC?

Do analysts rate CYRX or ALEC?

Does the media prefer CYRX or ALEC?

Is CYRX or ALEC more profitable?

Which has more risk and volatility, CYRX or ALEC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC vs. The Competition

Alector Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools